India's Orchid Pharma completes debt recast

India-based Orchid Chemicals and Pharmaceuticals has said that it completed the debt recast scheme that it had initiated in June last year

id-100259847

The RBI panel on debt recasts has cleared the Business Transfer Agreement that Orchid entered into with Hospira India in 2012

An Indian company, based in Chennai, Orchid Chemicals and Pharmaceuticals has said that it has completed the debt recast scheme that it had initiated last year.

As per the process, Orchid will pay back dues of ₹2,866 crore to a consortium of lenders over a period of 10 years.

Further, the Business Transfer Agreement that Orchid entered into with Hospira India in 2012 too has been cleared by the RBI panel on debt recast.

This agreement allows the company to pay-off a portion of its total debt of ₹3,547 crore and meet working capital requirements.

A news report pointed out that the proceeds of the sale to Hospira amount to
₹1,134 crore. In a statement to BSE, the company's managing director, Mr K Raghavendra Rao said, "With this development, the company is back on the growth path. With our inherent strength in the cephalosporins segment, our rebuilding process will be fast and robust."

 

Previous 1 Next

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

GST

GST: Boon or Bane for Healthcare?

Send this article by email

X